Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.

doi:10.1016/j.cllc.2011.03.008

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.

Clinical lung cancer - 1 Mar 2011

Farina Gabriella, Longo Flavia, Martelli Olga, Pavese Ida, Mancuso Andrea, Moscetti Luca, Labianca Roberto, Bertolini Alessandro, Cortesi Enrico, Farris Antonio, Fagnani Daniele, Locatelli Maria Cristina, Valmadre Giuseppe, Ardizzoia Antonio, Tomirotti Maurizio, Rulli Eliana, Garassino Marina Chiara, Scanni Alberto

Abstract excerpt

We present the rationale and study design of the Tarceva Italian Lung Optimization trial phase III, multicenter, open-label, randomized trial on efficacy of second-line therapies in different subgroups of non-small-cell lung cancer (NSCLC) patients identified using molecular and clinical evaluations. To date, we can assume that advanced NSCLC epidermal growth factor receptor (EGFR)-mutated patients benefit from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Docetaxel

Share to Erlotinib Hydrochloride

Share to Genes, ras

Share to Quality of Life

Share to Quinazolines

Share to Research Design

Share to Taxoids

Source

Open in PubMed

Identifiers

PMID: 21550561
DOI: 10.1016/j.cllc.2011.03.008

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.PMID 21550561Read ↗

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.Semantic proximity Read ↗

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).Semantic proximity Read ↗

LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.Semantic proximity Read ↗

Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study.Semantic proximity Read ↗

Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.Semantic proximity Read ↗

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.Semantic proximity Read ↗

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.Semantic proximity Read ↗

Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials.Semantic proximity Read ↗

EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition.Semantic proximity Read ↗

Pharmacogenetic Analysis of BR.21, a Placebo-Controlled Randomized Phase III Clinical Trial of Erlotinib in Advanced Non-small Cell Lung CancerSemantic proximity Read ↗

The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.